
Get in the KNOW
on LA Startups & Tech
XBionaut Labs Comes Out of Stealth To Reveal a Micro Robotic Treatment for Brain Tumors
Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

A small group of scientists and engineers are developing a device smaller than a flea that will wind its way inside the heads of people with brain tumors and deliver life-saving treatments.
Bionaut Labs, a Los Angeles startup, unveiled on Wednesday the tiny rigid remote-controlled device with metallic parts, a silica polymer exterior and a cavity to place treatments inside. It's a sort of drone for the body.
"This is the revolution and this is where it starts," said physicist and co-founder Michael Shpigelmacher. "I have no doubt that 10 years forward, there will be not one, but there will be multiple companies in this universe of ... remote-controlled micro robots."
Bionaut Labs began preclinical trials in 2018 to treat brainstem glioma, a tumor nestled in one of the most complex and delicate areas of the body — the brainstem, which controls everything from breathing to eating to heart rate. Because of its location, surgery is often not an option and some patients undergo radiation therapy.
"You really want to hit up that tumor and you don't want to just flood the whole body with a payload that would have significant toxicity or side effects," Shpigelmacher said.
Their "micro robot" or "Bionaut," as the company calls it, is still untested in humans. But, the device is meant to be injected by doctors into the brain and controlled with a magnetic device that moves it through the brain and to the affected area. Once treatment is complete, it's removed magnetically. It's biggest advantage, the company hopes, is to deliver targeted treatment, eliminating the need for physicians to turn to more invasive medicines such as radiation.
Physicist Michael Shpigelmacher is the co-founder of Bionaut Labs
"This is mostly useful for anatomical targets that are hard to reach where you need that level of anatomical precision," Shpigelmacher said.
He and his co-founders Aviad Maizels and Alex Shpunt previously worked together at a startup called PrimeScience that was later acquired by Apple in 2013. He began working with pharma companies in 2007, watching drugmakers formulate and reformulate drugs when they failed clinical trials.
Part of the problem is that medicine, most often pills, taken by patients flow through the bloodstream and often have side effects from depression and weight gain to even more serious ones. If it works, the Bionaut would only release chemicals to specific areas and not diffuse through a patient's bloodstream. That method, known as localized treatment, means drugs could be stronger and more targeted.
"That would maximize efficacy at the site of action, and minimize toxicity in all the places where it shouldn't have any activity," said Dr. Eunjoo Pacifici, a professor at the USC School of Pharmacy, about localized treatments.
But the process isn't easy. Drugs are highly regulated by the Food and Drug Administration. It can take years before a drug comes to market. Localized treatments often require a device to inject that treatment into the body. That, too, can take years for the FDA to approve.
"It's a combination product. Sometimes you need to have different parts of the FDA review that product as well. It's like developing two products at the same time," Pacifici said.
Bionauts are focused on brainstem glioma for now, but Shpigelmacher's background at McKinsey has him thinking big — the implications of Bionauts, he said, could change the way drugs are developed.
Pacifici said the drug-making process is a "high-stakes game" because companies often have to pump thousands of dollars into researching, developing and testing drugs without the promise of a return on investment. But if the FDA does not accept the benefit/ risk profile of a certain drug, it cannot get to the next step and be marketed or sold.
"You hope the product will do what you want it to do and there's some promising results in the lab, there's some promising results in the animals and the early stage clinical trials seem very promising," Pacifici said. "But then when you actually throw down the big money to conduct a big trial, more often than not it fails. A product can fail at any stage, but when it fails at a pivotal stage, it's a huge loss for the company."
If treatments can be localized, Shpigelmacher said, the amount of time companies spend in the research and development phase could shorten, and drugs would be conceptualized and tested to be used with a Bionaut.
The company raised $20 million in backing from Khosla Ventures, Upfront Ventures and Bold Capital.
Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.
Subscribe to our newsletter to catch every headline.
Venture Firm Backstage Capital Cuts Three-Quarters of Staff
Kristin Snyder is an editorial intern for dot.la. She previously interned with Tiger Oak Media and led the arts section for UCLA's Daily Bruin.
Venture firm Backstage Capital laid off nine employees, reducing its staff to just three.
Managing partner and founder Arlan Hamilton announced the layoffs Sunday on her “Your First Million” podcast. General partners Christie Pitts and Brittany Davis, along with Hamilton, are the only remaining employees, TechCrunch reported. The move comes only three months after the Los Angeles-based firm said it would only fund existing portfolio companies.
“It’s not that I feel like there’s any sort of failure on the fund side, on the firm’s side, on Backstage’s side, it’s that this could have been avoided if…the system we work within were different,” Hamilton said during the podcast.
Hamilton founded Backstage in 2015 to highlight underrepresented founders and launched a crowdfunding campaign last year to draw in everyday investors. The company announced its plan to raise $30 million for a new fund, bringing in $1 million from Comcast. Having invested in 200 companies, Backstage announced in March that it would not be making new investments.
Hamilton said Backstage’s situation is a “purgatory kind of position,” with companies saying the fund was either too developed or not developed enough to invest in. However, in an email sent to stakeholders, she said she is “optimistic about the next 18 months.”
The firm still intends to grow its assets under management to over $100 million as Hamilton looks for backing from to the 26 funds she has invested in for backing. Hamilton said the company does not “have dry powder right now,” which points to the firm’s struggle to grow.
The news comes during a wave of layoffs across Los Angeles, with companies like Voyage SMS, Albert and Bird letting go of employees.
- Going Public Show Was Built for the Retail Investor Uprising - dot.LA ›
- Backstage Capital Opens Fund to Everyday Investors - dot.LA ›
Kristin Snyder is an editorial intern for dot.la. She previously interned with Tiger Oak Media and led the arts section for UCLA's Daily Bruin.
A New Tide of LA Startups Is Tackling the National Childcare Crisis
Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.
The pandemic exacerbated a problem that has been long bubbling in the U.S.: the childcare crisis.
According to a survey of people in science, technology, engineering and mathematics (STEM) careers conducted by the city’s WiSTEM Los Angeles program and shared exclusively with dot.LA, the pandemic exposed a slew of challenges across STEM fields. The survey—which consisted of 181 respondents from L.A.County and was conducted between March 2021 and 2022— involved respondents across medical fields, technical professions and science industries who shared the pandemic’s effects on their professional or education careers.
The survey found 60% of the respondents, primarily women, were balancing increased caretaking roles with work or school responsibilities. And while caretaking responsibilities grew, 49% of respondents said their workload also increased during the pandemic.
“The pandemic threw a wrench into lots of folks' experiences both professionally and academically,” said Kathryne Cooper, a health tech investor who sits on the advisory board of WiSTEM. “So we need to acknowledge that.”
In the L.A. area, an increasing number of childcare startups are aiming to address this massive challenge that is a growing national crisis. The U.S. has long dealt with a crippling childcare infrastructure plagued by low wages and a labor shortage in preschools and daycares, but the COVID-19 crisis made it worse. During the pandemic, women left the workforce due to the lack of childcare and caretaking resources. By 2021, women made up the lowest percentage of the workforce since 1988, according to the National Women’s Law Center. Despite the pandemic forcing everyone indoors, caretaking duties fell disproportionately on women.
“I almost actually left my job because everything that I looked at was either waitlisted or the costs were so astronomical that it probably made sense for me to stay at home rather than pay someone to actually look after my child,” said Jessica Chang, the CEO of childcare startup WeeCare.
The Marina del Rey-based WeeCare, one of the startups that helps people open their own childcare facilities, announced it raised $12 million in April (to go along with an additional $5 million in bridge funding raised during the pandemic). The company helps people build daycare centers and works with employers to provide access to WeeCare centers and construct child care benefits programs.
Some of these startups strive to boost the number of daycare centers by helping operators with financial costs, licensing fees and scheduling. Wonderschool, a San Francisco-based child care startup, raised $25 million in January and assisted with hundreds of childcare facilities in L.A.-based Playground, which raised $3 million in seed funding last year per PitchBook. Playground acts as an in-house platform for childcare providers to communicate with staff and parents, track attendance, report student behavior and provide automatic invoicing services.
L.A.-based Brella, which launched in 2019, raised $5 million in seed funding in January to create a tech-enabled daycare scheduling platform that could meet the demand of flexible childcare as parents navigate a hybrid work environment, and recently opened a new location in Hollywood. The startup aims to address the labor shortage among childcare workers by paying its workers roughly $25 an hour and offering mental health benefits and career development opportunities for its educators.
“It's this huge disconnect in our society because these are really important people who are doing arguably one of the most important educational jobs,” said Melanie Wolff, co-founder of childcare startup Brella. “They often don't get benefits. They don't have a lot of job security.”
Venture capital funding has poured into the relatively new childcare sector. A slew of parent-tech companies aimed at finding flexible child care and monitoring children saw $1.4 billion worth of venture investments in 2021, according to PitchBook, largely to meet the demands of parents in a pandemic era who have more flexible work commutes and require more tech-enabled solutions.
“I think a lot of it has to do with what employers expect for workers,” said Darby Saxbe, an associate professor of psychology and family relationships expert at USC. “There's still a lot more stigma for men to build their work around caregiving responsibilities–there's a lot of evidence that men are often discouraged from taking paternity leave, even if it's available.”
Childcare benefits are also becoming a more attractive incentive as workers grapple with unorthodox work schedules in a hybrid setting.
“Employers, because of COVID, were having a hard time retaining and recruiting employees,” said Chang. “And they were actually incentivized to actually find a solution to help the employees.”
WeeCare primarily partners with employers of essential workers, like schools, hospitals and grocery stores, and the benefits programs account for the majority of WeeCare’s revenue.
Childcare works are part of a massive labor shortage in caretaker roles that also include nurses, and health aids for the eldery. These workers, which allow women to maintain careers in STEM and other high-paying industries, are vital, according to Saxbe.
“Women can advance in the workplace,” Saxbe said. “But if there's no support at home and there is no one who is helping take care of kids and elderly people, women can't just advance in a vacuum.”
- The Wana Family Childcare Network is Booming - dot.LA ›
- Childcare Providers Get a Lifeline From LA Startup WeeCare ›
- Childcare Center Brella Raises $5 Million, New LA Locations - dot.LA ›
- WeeCare Raises $17 Million As Childcare Startups Boom - dot.LA ›
Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.
“Talent Is Ubiquitous; Access to Capital Is Not': MaC Venture Capital Raises $203M for Early-Stage Startups
Decerry Donato is dot.LA's Editorial Fellow. Prior to that, she was an editorial intern at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.
While venture capital funding has taken a hit this year, that hasn’t stopped MaC Venture Capital from raising $203 million for its second fund.
The Los Angeles-based, Black-led VC firm said Monday that it had surpassed its initial $200 million goal for the fund, which dot.LA reported in January, over the span of seven months. MaC said it expects to invest the capital in up to 50 mostly seed-stage startups while remaining “sector-agnostic.”
“We love seed-stage companies because that’s where most of the value is created,” MaC managing general partner Marlon Nichols told dot.LA. While the firm has invested in local ventures like NFT gaming platform Artie, space startup Epsilon3 and autonomous sensor company Spartan Radar, Nichols said MaC—whose portfolio companies span from Seattle to Nairobi—would continue to eye ventures across the rest of the country and world.
“Talent is ubiquitous; access to capital is not,” Nichols noted. “What they’re building needs to matter; we’ve got to believe that this group of founders is the best team building in the space, period.”
Launched in 2019, MaC is led by four founding partners: VC veteran Nichols, former Washington, D.C. mayor Adrian Fenty, and former William Morris Endeavor talent agents Charles D. King and Michael Palank. Nichols described the team’s collective background in government, consulting, media, entertainment and talent management as its “superpower.”
In a venture capital industry where few people of color are decision-makers, MaC Venture Capital has looked to wield its influence to provide opportunities for founders of color. The firm says 69% of its portfolio companies were started by BIPOC founders and 36% are led by women, while MaC has also diversified its own ranks by adding female partners Zhenni Liu and Haley Farnsworth.
MaC’s second investment fund nearly doubled the size of the firm’s $110 million first fund, which it closed in March 2021. The new fund’s repeat institutional investors include Goldman Sachs, ICG Advisors, StepStone, the University of Michigan, the George Kaiser Family Foundation and the MacArthur Foundation, while the likes of Illumen Capital and the Teachers’ Retirement System of the State of Illinois also pitched in as new investors.
“It’s a great combination of having affirmation from people who have been with us from the beginning and new people coming in that want to be a part of it,” Fenty told dot.LA.
- Can MaC VC Help Solve Tech's Whiteness Problem? - dot.LA ›
- MaC Venture Capital's Marlon Nichols on 'Diversity Theater' - dot.LA ›
- MaC Venture Capital Eyes $200 Million For Its Second Fund - dot.LA ›
Decerry Donato is dot.LA's Editorial Fellow. Prior to that, she was an editorial intern at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.